Xeris Biopharma Holdings
XERS
162 hedge funds and large institutions have $223M invested in Xeris Biopharma Holdings in 2024 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 60 increasing their positions, 33 reducing their positions, and 12 closing their positions.
263% more call options, than puts
Call options by funds: $857K | Put options by funds: $236K
158% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 12
82% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 33
22% more capital invested
Capital invested by funds: $182M → $223M (+$40.6M)
13% more funds holding
Funds holding: 144 → 162 (+18)
1.18% more ownership
Funds ownership: 42.9% → 44.08% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$4.67M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$2.68M |
| 3 |
Goldman Sachs
New York
|
+$2.43M |
| 4 |
JP Morgan Chase
New York
|
+$2.1M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$1.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$9.97M |
| 2 |
CP
CenterBook Partners
Greenwich,
Connecticut
|
-$8.98M |
| 3 |
Walleye Capital
New York
|
-$3.2M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$1.92M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$750K |
XERS Hedge Fund Activity: Q4 2024 in Review
162 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q4 2024, worth a combined $223M — up 22% from $182M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new XERS positions and 12 closed out — a net gain of 19 holders — while 60 added to existing stakes and 33 trimmed.
The largest buyer was UBS Group, adding an estimated $4.67M. The largest seller was Caxton Corporation, cutting an estimated $9.97M.
- 162 institutional investors held Xeris Biopharma Holdings (XERS) as of Q4 2024, up from 144 in Q3 2024.
- Funds reported $223M of Xeris Biopharma Holdings stock for Q4 2024, up 22% quarter-over-quarter.
- 31 funds opened new Xeris Biopharma Holdings positions in Q4 2024 and 12 closed out, a net change of +19 holders.
- The largest Xeris Biopharma Holdings buyer in Q4 2024 was UBS Group, an estimated $4.67M added.
- The largest Xeris Biopharma Holdings seller in Q4 2024 was Caxton Corporation, an estimated $9.97M sold.
Based on aggregated 13F filings for Q4 2024.